Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 12:07 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2545–2568 of 4,272 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Blood samples collected Clear all

Conditions: Cancer
Interventions: urine samples (biomarkers), blood samples (biomarkers), blood sample (DNA); Other
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2018
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: THC, Cannabis, Cannabis Smoking, Cannabis Use, Unspecified, Cigarette Smoking, Tobacco Use, Nicotine Dependence, Nicotine Withdrawal, Cardiovascular Risk Factor
Interventions: Smoked Cannabis, Vaped Cannabis, Tobacco Cigarette; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 21 Years and older
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 2
States / cities: San Francisco, California

Conditions: Desmoplastic Small Round Cell Tumor, Osteosarcoma, Recurrent Desmoplastic Small Round Cell Tumor, Recurrent Kidney Wilms Tumor, Recurrent Osteosarcoma, Refractory Desmoplastic Small Round Cell Tumor, Refractory Wilms Tumor, Wilms Tumor
Interventions: Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Trastuzumab Deruxtecan; Procedure · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 12 Years to 39 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 32
States / cities: Birmingham, Alabama • Los Angeles, California • Orange, California + 27 more

Conditions: Disease Progression
Interventions: De novo tumor tissue biopsy, Research blood draws; Procedure
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 17
States / cities: Daphne, Alabama • Mobile, Alabama • Anchorage, Alaska + 10 more

Conditions: Acute Monocytic Leukemia, Acute Myeloid Leukemia
Interventions: Azacitidine, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Cladribine, Cytarabine, Echocardiography, Lumbar Puncture, Multigated Acquisition Scan, Questionnaire Administration, Venetoclax; Drug · Procedure · Other
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: Miami, Florida • Portland, Oregon

Conditions: Cutaneous Melanoma, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma
Interventions: Exercise, Checkpoint Blockade, Immune; Other · Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Diphtheria, Hepatitis B, Pertussis, Poliomyelitis, Tetanus
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 2005
U.S. locations: 1
States / cities: Torrance, California

Conditions: Precancerous Condition, Prostate Cancer
Interventions: immunoenzyme technique, laboratory biomarker analysis; Other
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 45 Years to 65 Years · Male only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2011
U.S. locations: 3
States / cities: Cleveland, Ohio

Conditions: Leukemia, Acute Myelogenous (AML), Leukemia, Acute Lymphocytic (ALL), Leukemia, Chronic Myelogenous (CML), Myelodysplastic Syndrome (MDS), Non-Hodgkin's Lymphoma (NHL)
Interventions: WT1 Peptide-Pulsed Dendritic Cells, Donor Lymphocytes, IL-4, KLH, WT1 Peptides, Endotoxin, Diphenhydramine, Acetaminophen; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 1 Year to 74 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Lymphoma, Nonneoplastic Condition
Interventions: polymerase chain reaction, laboratory biomarker analysis; Genetic · Other
Lead sponsor: AIDS Malignancy Consortium; Network
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 16
States / cities: La Jolla, California • Los Angeles, California • Sacramento, California + 11 more

Conditions: Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Breast Adenocarcinoma, HER2/Neu Negative, Locally Advanced Breast Carcinoma, Metastatic Breast Carcinoma, Recurrent Breast Carcinoma
Interventions: Biospecimen Collection, Computed Tomography, Entinostat, Exemestane, Goserelin, Goserelin Acetate, Magnetic Resonance Imaging, Placebo Administration, Quality-of-Life Assessment; Procedure · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 608 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2027
U.S. locations: 652
States / cities: Birmingham, Alabama • Jonesboro, Arkansas • Carmichael, California + 460 more

Conditions: Labor Pain, Post-cesarean Delivery
Interventions: Blood Draw; Procedure
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 293 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Vitamin D Deficiency
Interventions: Not listed
Lead sponsor: Fujirebio Diagnostics, Inc.; Industry
Eligibility: Not listed
Enrollment: 482 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Mountain View, California

Conditions: Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions: Echocardiogram Recording, Questionnaire Administration, Stress Cardiac Magnetic Resonance Imaging, Wireless Synchronized Cardiac Function Monitoring Device; Procedure · Other · Device
Lead sponsor: City of Hope Medical Center; Other
Eligibility: Not listed
Enrollment: 149 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Duarte, California

Conditions: Erythroplakia, Oral Leukoplakia
Interventions: Biopsy, Biospecimen Collection, Extended Release Metformin Hydrochloride, Placebo Administration; Procedure · Drug
Lead sponsor: University of Arizona; Other
Eligibility: 21 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 8
States / cities: Tucson, Arizona • San Diego, California • Tampa, Florida + 5 more

Conditions: Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Locally Advanced Lung Carcinoma, Locally Advanced Malignant Solid Neoplasm, Locally Advanced Melanoma, Metastatic Lung Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
Interventions: Biospecimen Collection, Electronic Health Record Review; Procedure · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2028
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Lymphoma
Interventions: laboratory biomarker analysis; Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Metabolic Dysfunction Associated Steatotic Liver Disease, Non-Alcoholic Fatty Liver Disease (NAFLD)
Interventions: Velacur, MRI, Blood sample collection for biomarkers, Liver biopsy; Diagnostic Test
Lead sponsor: Emory University; Other
Eligibility: 2 Years to 20 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Recurrent Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm, Uveal Melanoma, Acral Melanoma, Neuroendocrine Tumors, Paraganglioma, Pheochromocytoma, Adrenocortical Carcinoma, Pancreatic Neuroendocrine Tumor, Thyroid Cancer, Breast Cancer, Lung Adenocarcinoma, Head and Neck Squamous Cell Carcinoma
Interventions: Biopsy, Biospecimen Collection, Computed Tomography, Cyclophosphamide, Fludarabine Phosphate, Fludeoxyglucose F-18, IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells, Magnetic Resonance Imaging, Positron Emission Tomography; Procedure · Drug · Other + 1 more
Lead sponsor: Anusha Kalbasi; Other
Eligibility: 18 Years to 75 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 3
States / cities: Duarte, California • Los Angeles, California • Stanford, California

Conditions: Lung Cancer
Interventions: Lung MRI, Blood Draw; Diagnostic Test
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 50 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Hypoglycemia
Interventions: Continuous Glucose Monitoring, activity monitor, Mixed meal tolerance test, Glucagon Sensitivity Testing, Hypoglycemic Hyperinsulinemic Clamp, analysis of fecal microbiome; Diagnostic Test
Lead sponsor: Joslin Diabetes Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 105 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Multiple Myeloma
Interventions: Structural Image, Functional Image, Digit Span subtest, Brief Test of Attention, Trail Making Test (Parts A & B), Auditory Consonant Trigrams Test, Controlled Oral Word Association Test, Hopkins Verbal Learning Test-Revised, The Center for Epidemiological Study-Depression, The Functional Assessment of Chronic Illness Therapy-Fatigue Subscale, Version 4, Blood draw; Diagnostic Test · Behavioral · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 60 Years to 75 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 2
States / cities: New Brunswick, New Jersey • New York, New York

Conditions: Hyperglycaemia (Diabetic)
Interventions: Insulin, exercise, Dietary counseling; Drug · Behavioral · Dietary Supplement
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Multiple Myeloma
Interventions: Thalidomide, Ara-C, BCNU, Cisplatin, Cytoxan, Dexamethasone, Doxorubicin, Etoposide, Filgrastim, Recombinant GM-CSF, Interferon-alpha-2b, Melphalan, Vincristine; Drug
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years to 75 Years
Enrollment: 668 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2014
U.S. locations: 1
States / cities: Little Rock, Arkansas

Search by objective public record fields.

Investigation of Cisplatin-Related Kidney Toxicity

THC Crossover Study

Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor

Treatment Resistance Following Anti-cancer Therapies

Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML

Exercise to Boost Response to Checkpoint Blockade Immunotherapy

Pilot Study Freeze and Transport Immune Cells

Study of Blood Samples From Older Patients at High Risk of Developing Prostate Cancer and From Healthy Male Participants

Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the Blood

Study of Blood and Tissue Samples From Patients With Aggressive Non-Hodgkin B-Cell Lymphoma or Hodgkin Lymphoma

Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic

Mu-Opioid Receptor Genetic Polymorphism and Intrathecal Analgesia

Study Vitamin D in Healthy Individuals

Reproducibility and Accuracy of a Portable System for Early Detection of Cardiac Dysfunction in Childhood Cancer Survivors

Metformin for the Prevention of Oral Cancer in Patients With Oral Leukoplakia or Erythroplakia

Evaluation of Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types

DNA Analysis in Predicting Response to Antibody Therapy in Patients With Follicular Lymphoma Treated on Clinical Trials CALGB-50402 or CALGB-50701

Non-Invasive Diagnostic Tests for MASLD in Pediatric Population

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

MRI and Biomarkers for Lung Nodules Detected During Lung Cancer Screening

Mechanisms of Post-Bariatric Hypoglycemia

Neurocognitive and Neuroimaging Outcomes in Older Patients With Multiple Myeloma Treated With Autologous Stem Cell Transplantation

Investigating the Role of the Polyol Pathway in the Central Nervous System Production of Fructose

UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy